Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer.
about
The environment of regulatory T cell biology: cytokines, metabolites, and the microbiomeNew insights into the mechanisms of Treg functionGeneration, cryopreservation, function and in vivo persistence of ex vivo expanded cynomolgus monkey regulatory T cells.Targeting Sirtuin-1 prolongs murine renal allograft survival and function.Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft RecipientsPharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants.Treg-Centric View of Immunosuppressive Drugs in Transplantation: A Balancing Act.Transplant trials with Tregs: perils and promises.The Leuven Immunomodulatory Protocol Promotes T-Regulatory Cells and Substantially Prolongs Survival After First Intestinal Transplantation.Pharmacokinetics of therapeutic Tregs.Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation.T cell receptor repertoires after adoptive transfer of expanded allogeneic regulatory T cells.Adoptive Cell Therapy with Tregs to Improve Transplant Outcomes: The Promise and the Stumbling Blocks.Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.Transcriptomic analysis of crustacean molting gland (Y-organ) regulation via the mTOR signaling pathway.
P2860
Q21131158-60412300-7534-4B4E-86A4-DA88B4A39A58Q26823540-665F5324-EE78-4F71-8024-DF9177BABB0AQ35514307-1B98A1BF-BE97-408E-B0E3-B7FE35A676A0Q36805252-1FD30415-9D89-45B8-AE70-F5FE120F88C0Q37033965-EE98FA10-13B3-4E84-A690-02EF294873C8Q38614123-BB26D4C5-2D3A-4D04-8EC7-05D5250980BFQ38662974-B2EC371A-78CD-44FD-989C-311AB24CA693Q38942832-C02C4CAC-3F92-43A7-870E-22609A64BACDQ39406891-1F4B764D-C1B7-4F1F-B837-78C6D0E14012Q40731460-19B5C934-FBDB-41BC-8DDB-1811A1B012A9Q46253781-73A4C175-58C1-49E1-8949-3B221D5E017FQ46458062-68027FFE-A992-402F-B1B5-B1FD06FF9F73Q47275057-4AEDDE42-CE17-442B-A4A2-515F80CBA068Q48592108-D7EA831C-D723-42E3-A59B-294F77484EB3Q50632486-C8D36A2F-CB5F-4608-9FB8-7C056CCB151FQ52927960-0BCA4950-7B22-4581-A995-B23B45D9B2C3Q54111176-D9266B0E-7CAF-4150-B929-2B055312F82F
P2860
Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Superiority of rapamycin over ...... otype after adoptive transfer.
@ast
Superiority of rapamycin over ...... otype after adoptive transfer.
@en
Superiority of rapamycin over ...... otype after adoptive transfer.
@nl
type
label
Superiority of rapamycin over ...... otype after adoptive transfer.
@ast
Superiority of rapamycin over ...... otype after adoptive transfer.
@en
Superiority of rapamycin over ...... otype after adoptive transfer.
@nl
prefLabel
Superiority of rapamycin over ...... otype after adoptive transfer.
@ast
Superiority of rapamycin over ...... otype after adoptive transfer.
@en
Superiority of rapamycin over ...... otype after adoptive transfer.
@nl
P2093
P2860
P356
P1476
Superiority of rapamycin over ...... otype after adoptive transfer.
@en
P2093
P2860
P304
P356
10.1111/AJT.12934
P407
P577
2014-10-30T00:00:00Z